Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration.

Cooper A, García M, Petrovas C, Yamamoto T, Koup RA, Nabel GJ.

Nature. 2013 Jun 20;498(7454):376-9. doi: 10.1038/nature12274. Epub 2013 Jun 5.

PMID:
23739328
2.

HIV integration and T cell death: additional commentary.

Cooper A, García M, Petrovas C, Yamamoto T, Koup RA, Nabel GJ.

Retrovirology. 2013 Dec 9;10:150. doi: 10.1186/1742-4690-10-150.

3.

HIV integrase and the swan song of the CD4 T cells?

Estaquier J, Zaunders J, Laforge M.

Retrovirology. 2013 Dec 9;10:149. doi: 10.1186/1742-4690-10-149.

4.

HIV: Integration triggers death.

Skalka AM.

Nature. 2013 Jun 20;498(7454):305-6. doi: 10.1038/nature12254. Epub 2013 Jun 5. No abstract available.

PMID:
23739334
6.

[Potential of integrase inhibitors to deplete HIV reservoirs or prevent their replenishment].

Llibre JM, Martínez-Picado J.

Enferm Infecc Microbiol Clin. 2008 Nov;26 Suppl 12:17-22. Review. Spanish.

PMID:
19572421
7.

A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs.

Lassen KG, Hebbeler AM, Bhattacharyya D, Lobritz MA, Greene WC.

PLoS One. 2012;7(1):e30176. doi: 10.1371/journal.pone.0030176. Epub 2012 Jan 24.

8.

LEDGIN-mediated Inhibition of Integrase-LEDGF/p75 Interaction Reduces Reactivation of Residual Latent HIV.

Vranckx LS, Demeulemeester J, Saleh S, Boll A, Vansant G, Schrijvers R, Weydert C, Battivelli E, Verdin E, Cereseto A, Christ F, Gijsbers R, Debyser Z.

EBioMedicine. 2016 Jun;8:248-64. doi: 10.1016/j.ebiom.2016.04.039. Epub 2016 May 13.

9.

Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivo.

Goffinet C, Allespach I, Oberbremer L, Golden PL, Foster SA, Johns BA, Weatherhead JG, Novick SJ, Chiswell KE, Garvey EP, Keppler OT.

J Virol. 2009 Aug;83(15):7706-17. doi: 10.1128/JVI.00683-09. Epub 2009 May 20.

10.

P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gphigh cells and correlates with HIV-1 viral load.

Minuesa G, Arimany-Nardi C, Erkizia I, Cedeño S, Moltó J, Clotet B, Pastor-Anglada M, Martinez-Picado J.

J Antimicrob Chemother. 2016 Oct;71(10):2782-92. doi: 10.1093/jac/dkw215. Epub 2016 Jun 21.

11.

The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.

Lucera MB, Tilton CA, Mao H, Dobrowolski C, Tabler CO, Haqqani AA, Karn J, Tilton JC.

J Virol. 2014 Sep;88(18):10803-12. doi: 10.1128/JVI.00320-14. Epub 2014 Jul 9.

12.

Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages.

Marsden MD, Avancena P, Kitchen CM, Hubbard T, Zack JA.

Antimicrob Agents Chemother. 2011 Aug;55(8):3696-702. doi: 10.1128/AAC.00566-11. Epub 2011 May 31.

13.

Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations.

Varadarajan J, McWilliams MJ, Hughes SH.

Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14747-52. doi: 10.1073/pnas.1305066110. Epub 2013 Aug 19.

14.

Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells.

Saleh S, Wightman F, Ramanayake S, Alexander M, Kumar N, Khoury G, Pereira C, Purcell D, Cameron PU, Lewin SR.

Retrovirology. 2011 Oct 12;8:80. doi: 10.1186/1742-4690-8-80.

16.

Analysis of protein kinase C theta inhibitors for the control of HIV-1 replication in human CD4+ T cells reveals an effect on retrotranscription in addition to viral transcription.

Bermejo M, López-Huertas MR, Hedgpeth J, Mateos E, Rodríguez-Mora S, Maleno MJ, Plana M, Swindle J, Alcamí J, Coiras M.

Biochem Pharmacol. 2015 Apr 15;94(4):241-56. doi: 10.1016/j.bcp.2015.02.009. Epub 2015 Feb 27.

PMID:
25732195
17.

HIV integration and the establishment of latency in CCL19-treated resting CD4(+) T cells require activation of NF-κB.

Saleh S, Lu HK, Evans V, Harisson D, Zhou J, Jaworowski A, Sallmann G, Cheong KY, Mota TM, Tennakoon S, Angelovich TA, Anderson J, Harman A, Cunningham A, Gray L, Churchill M, Mak J, Drummer H, Vatakis DN, Lewin SR, Cameron PU.

Retrovirology. 2016 Jul 26;13(1):49. doi: 10.1186/s12977-016-0284-7.

18.

An HIV-1 replication pathway utilizing reverse transcription products that fail to integrate.

Trinité B, Ohlson EC, Voznesensky I, Rana SP, Chan CN, Mahajan S, Alster J, Burke SA, Wodarz D, Levy DN.

J Virol. 2013 Dec;87(23):12701-20. doi: 10.1128/JVI.01939-13. Epub 2013 Sep 18.

19.

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Buzón MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, Gatell JM, Domingo P, Paredes R, Sharkey M, Palmer S, Stevenson M, Clotet B, Blanco J, Martinez-Picado J.

Nat Med. 2010 Apr;16(4):460-5. doi: 10.1038/nm.2111. Epub 2010 Mar 14.

PMID:
20228817
20.

Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo.

Zimmerman ES, Sherman MP, Blackett JL, Neidleman JA, Kreis C, Mundt P, Williams SA, Warmerdam M, Kahn J, Hecht FM, Grant RM, de Noronha CM, Weyrich AS, Greene WC, Planelles V.

J Virol. 2006 Nov;80(21):10407-18. Epub 2006 Sep 6.

Supplemental Content

Support Center